Abstract
Multimodal imaging agents were first introduced a decade ago and consist of a targeting moiety that is dual-labeled with radioactive and fluorescent contrast. These compounds allow whole-body and intraoperative imaging to be performed through administration of a single agent and provide complementary diagnostic information that can be used to guide tumor resection. Since their initial evaluation, interest in dual-labeled agents has continued to grow and their design has subsequently evolved alongside the development of novel chelating agents, improved fluorophores, and highly selective coupling techniques for bioconjugate formation. In this review, will discuss how changes in the labeling components and schemes for multimodal agent development have impacted imaging performance and will focus on antibody- and peptide-based agents as models for dual labeling. We will also describe the growing role of modular dual labeling strategies as well as direct labeling methods using radiohalogens.
Keywords: Dual labeling, molecular imaging, multimodality, near-infrared fluorescence, radioisotope, nuclear imaging.
Current Medicinal Chemistry
Title:Advances in the Development of Multimodal Imaging Agents for Nuclear/Near-infrared Fluorescence Imaging
Volume: 22 Issue: 29
Author(s): S.C. Ghosh and A. Azhdarinia
Affiliation:
Keywords: Dual labeling, molecular imaging, multimodality, near-infrared fluorescence, radioisotope, nuclear imaging.
Abstract: Multimodal imaging agents were first introduced a decade ago and consist of a targeting moiety that is dual-labeled with radioactive and fluorescent contrast. These compounds allow whole-body and intraoperative imaging to be performed through administration of a single agent and provide complementary diagnostic information that can be used to guide tumor resection. Since their initial evaluation, interest in dual-labeled agents has continued to grow and their design has subsequently evolved alongside the development of novel chelating agents, improved fluorophores, and highly selective coupling techniques for bioconjugate formation. In this review, will discuss how changes in the labeling components and schemes for multimodal agent development have impacted imaging performance and will focus on antibody- and peptide-based agents as models for dual labeling. We will also describe the growing role of modular dual labeling strategies as well as direct labeling methods using radiohalogens.
Export Options
About this article
Cite this article as:
Ghosh S.C. and Azhdarinia A., Advances in the Development of Multimodal Imaging Agents for Nuclear/Near-infrared Fluorescence Imaging, Current Medicinal Chemistry 2015; 22 (29) . https://dx.doi.org/10.2174/0929867322666150904111214
DOI https://dx.doi.org/10.2174/0929867322666150904111214 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metronomic Therapy for Multi Relapsed/Refractory Lymphoma. A Pilot Study
Current Angiogenesis (Discontinued) Bacterial Biotransformation and Anticancer Activities of Betulin against A549, HepG2 and 5RP7 Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Array-Based Approaches for the Identification of Epigenetic Silenced Tumor Suppressor Genes
Current Genomics Chemical Composition and Biological Activity of Essential Oils of Cumin and Coriander Fruits from Egypt
The Natural Products Journal Mitochondrial Permeability Transition as Target of Anticancer Drugs
Current Pharmaceutical Design Effects of Nanosuspension Formulations on Transport, Pharmacokinetics, In Vivo Targeting and Efficacy for Poorly Water-soluble Drugs
Current Pharmaceutical Design Cancer Stem Cell Model in Oral Squamous Cell Carcinoma
Current Stem Cell Research & Therapy Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer
Current Drug Targets Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography
Current Pharmaceutical Design Topoisomerase 1B as a Target Against Leishmaniasis
Mini-Reviews in Medicinal Chemistry Cucurbitacin B Induces DNA Damage, G2/M Phase Arrest, and Apoptosis Mediated by Reactive Oxygen Species (ROS) in Leukemia K562 Cells
Anti-Cancer Agents in Medicinal Chemistry Natural Product-Derived Spirooxindole Fragments Serve as Privileged Substructures for Discovery of New Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Docking Prediction for Luteolin Inhibiting TNF-α and NF-κB Pathway
Letters in Drug Design & Discovery Nanoparticles in Gastric Cancer Management
Current Pharmaceutical Design Perspectives of Choroidal Neovascularization Therapy
Current Drug Targets Identification of Small Molecule Sulfonic Acids as Ecto-5'-Nucleotidase Inhibitors
Medicinal Chemistry Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Taxus-based Drug Development
Current Drug Metabolism Plant Troponoids: Chemistry, Biological Activity, and Biosynthesis
Current Medicinal Chemistry Zebrafish as a Model System to Screen Radiation Modifiers
Current Genomics Yoga can Alter the Autonomic Neural Activity: A Critical Analysis
Current Traditional Medicine